Viscient Biosciences

Featured

AMS 2021: Deconstructing the Timeline to Bioprinted Organs

Automation, healthcare, metal additive manufacturing (AM), and bioprinting were the four big topics discussed at the 2021 Additive Manufacturing Strategies (AMS) summit. The two-day virtual event gathered experts for panel…

Featured

Organovo’s Keith Murphy Back as Executive Chairman

Founder and former CEO of Organovo, Keith Murphy, is back as the company’s newly appointed Executive Chairman of the Board. The news comes three years after Murphy left the pioneering…

Viscient Biosciences is Leveraging 3D Bioprinting for Drug Discovery

Biotechnology companies are uncovering new methods to develop drugs across a range of therapeutic areas. Looking to demonstrate a commitment to drug discovery and moving away from traditional laboratory animal…

Keith Murphy: “We Believe We are Discovering the Next Step in Drug Development”

It’s been three years since Keith Murphy and Jeffrey Miner joined forces to create the biotechnology company Viscient Biosciences. In 2017, the co-founders had recently left their previous successful enterprises…

Cellink and Viscient’s Projects Will Aid Pandemic Research

The novel COVID-19 outbreak has altered the world at its core, transforming the foundation of most companies as economies begin to shut down to avoid a healthcare system collapse. In…

Organovo & Viscient Biosciences Collaborate for 3D Bioprinting in Liver Disease Research

Earlier this month, both Organovo and Viscient Biosciences announced their intent to collaborate on research for further studies into liver disease. There have been many interesting stories about Organovo and…